Capecitabine and Oxaliplatin (XELOX) Is Safe and Effective in Patients With Advanced Gastric Cancer

Acta Oncologica - United Kingdom
doi 10.1080/02841860701253060
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

2318 Prospective Phase II Trial of Pazopanib Plus CapeOX (Capecitabine and Oxaliplatin) in Previously Untreated Patients With Advanced Gastric Cancer

European Journal of Cancer
Cancer ResearchOncology
2015English

A Phase 1 Study of Irinotecan, Capecitabine (Xeloda®), and Oxaliplatin (IXO) in Patients With Advanced Colorectal Cancer

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

S-1 With Leucovorin and Oxaliplatin for Advanced Gastric Cancer

The Lancet Oncology
Oncology
2016English

Capecitabine and Oxaliplatin Prior and Concurrent to Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer: Long-Term Outcome

Clinical Colorectal Cancer
OncologyGastroenterology
2017English

A Multi-Center Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2008English

Mp02-08 Holep in Patients With Low Risk Prostate Cancer Is Safe and Effective

Journal of Urology
Urology
2017English

Capecitabine and Oxaliplatin Versus 5-Fluorouracil in the Neoadjuvant Chemoradiation for Patients With Locally Advanced Rectal Carcinoma: A Comparative Study

Journal of Cancer Therapy
2018English

Should S-1 Be Better Than Capecitabine for Patients With Advanced Gastric Cancer in Asia? A Systematic Review and Meta-Analysis

OncoTargets and Therapy
OncologyPharmacology
2018English

Is "Safe Effective Glucose Control" Effective and Safe?

Critical Care
Critical CareIntensive Care Medicine
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy